Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours

This study has been withdrawn prior to enrollment.
(Amendment to study compound development programme)
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01194193
First received: August 18, 2010
Last updated: May 13, 2011
Last verified: May 2011

August 18, 2010
May 13, 2011
Not Provided
Not Provided
  • Safety and tolerability of AZD8055; The number of patients with adverse events, including changes in vital signs, general organ function, clinical chemistry, haematology, urinalysis and physical examinations. [ Time Frame: Evaluability period is 5 weeks (visit 5), although safety and tolerability parameters will be measured at all visits. ] [ Designated as safety issue: Yes ]
  • Safety and tolerability of AZD8055; The number of patients with adverse events, including changes in vital signs, general organ function, clinical chemistry, haematology, urinalysis and physical examinations. [ Time Frame: Evaluability period is 5 weeks (visit 6), although safety and tolerability parameters will be measured at all visits. ] [ Designated as safety issue: Yes ]
  • Safety and tolerability of AZD8055; The number of patients with adverse events, including changes in vital signs, general organ function, clinical chemistry, haematology, urinalysis and physical examinations. [ Time Frame: Evaluability period is 5 weeks (visit 7), although safety and tolerability parameters will be measured at all visits. ] [ Designated as safety issue: Yes ]
  • Safety and tolerability of AZD8055; The number of patients with adverse events, including changes in vital signs, general organ function, clinical chemistry, haematology, urinalysis and physical examinations. [ Time Frame: Evaluability period is 5 weeks (visit 8), although safety and tolerability parameters will be measured at all visits. ] [ Designated as safety issue: Yes ]
  • Safety and tolerability of AZD8055; The number of patients with adverse events, including changes in vital signs, general organ function, clinical chemistry, haematology, urinalysis and physical examinations. [ Time Frame: Evaluability period is 5 weeks (visit 9), although safety and tolerability parameters will be measured at all visits. ] [ Designated as safety issue: Yes ]
  • Safety and tolerability of AZD8055; The number of patients with adverse events, including changes in vital signs, general organ function, clinical chemistry, haematology, urinalysis and physical examinations. [ Time Frame: Evaluability period is 5 weeks (visit 10), although safety and tolerability parameters will be measured at all visits. ] [ Designated as safety issue: Yes ]
  • Safety and tolerability of AZD8055; The number of patients with adverse events, including changes in vital signs, general organ function, clinical chemistry, haematology, urinalysis and physical examinations. [ Time Frame: Evaluability period is 5 weeks (visit 11), although safety and tolerability parameters will be measured at all visits. ] [ Designated as safety issue: Yes ]
  • Safety and tolerability of AZD8055; The number of patients with adverse events, including changes in vital signs, general organ function, clinical chemistry, haematology, urinalysis and physical examinations. [ Time Frame: Evaluability period is 5 weeks (visit 12), although safety and tolerability parameters will be measured at all visits. ] [ Designated as safety issue: Yes ]
  • Safety and tolerability of AZD8055; The number of patients with adverse events, including changes in vital signs, general organ function, clinical chemistry, haematology, urinalysis and physical examinations. [ Time Frame: Evaluability period is 5 weeks (visit 13), although safety and tolerability parameters will be measured at all visits. ] [ Designated as safety issue: Yes ]
  • Safety and tolerability of AZD8055; The number of patients with adverse events, including changes in vital signs, general organ function, clinical chemistry, haematology, urinalysis and physical examinations. [ Time Frame: Evaluability period is 5 weeks (visit 14), although safety and tolerability parameters will be measured at all visits. ] [ Designated as safety issue: Yes ]
  • Evaluate the pharmacokinetics of AZD8055; Pharmacokinetic analysis of the plasma and urine concentration data for AZD8055 and its metabolites will be performed following both single and multiple dosing with two intermittent dosing schedules. [ Time Frame: 1 cycle (3-4 weeks, at visit 2) ] [ Designated as safety issue: No ]
  • Evaluate the pharmacokinetics of AZD8055; Pharmacokinetic analysis of the plasma and urine concentration data for AZD8055 and its metabolites will be performed following both single and multiple dosing with two intermittent dosing schedules. [ Time Frame: 1 cycle (3-4 weeks, at visit 3) ] [ Designated as safety issue: No ]
  • Evaluate the pharmacokinetics of AZD8055; Pharmacokinetic analysis of the plasma and urine concentration data for AZD8055 and its metabolites will be performed following both single and multiple dosing with two intermittent dosing schedules. [ Time Frame: 1 cycle (3-4 weeks, at visit 4) ] [ Designated as safety issue: No ]
  • Evaluate the pharmacokinetics of AZD8055; Pharmacokinetic analysis of the plasma and urine concentration data for AZD8055 and its metabolites will be performed following both single and multiple dosing with two intermittent dosing schedules. [ Time Frame: 1 cycle (3-4 weeks, at visit 6) ] [ Designated as safety issue: No ]
  • Evaluate the pharmacokinetics of AZD8055; Pharmacokinetic analysis of the plasma and urine concentration data for AZD8055 and its metabolites will be performed following both single and multiple dosing with two intermittent dosing schedules. [ Time Frame: 1 cycle (3-4 weeks, at visit 7) ] [ Designated as safety issue: No ]
  • Evaluate the pharmacokinetics of AZD8055; Pharmacokinetic analysis of the plasma and urine concentration data for AZD8055 and its metabolites will be performed following both single and multiple dosing with two intermittent dosing schedules. [ Time Frame: 1 cycle (3-4 weeks, at visit 8) ] [ Designated as safety issue: No ]
  • Evaluate the pharmacokinetics of AZD8055; Pharmacokinetic analysis of the plasma and urine concentration data for AZD8055 and its metabolites will be performed following both single and multiple dosing with two intermittent dosing schedules. [ Time Frame: 1 cycle (3-4 weeks, at visit 9) ] [ Designated as safety issue: No ]
  • Evaluate the pharmacokinetics of AZD8055; Pharmacokinetic analysis of the plasma and urine concentration data for AZD8055 and its metabolites will be performed following both single and multiple dosing with two intermittent dosing schedules. [ Time Frame: 1 cycle (3-4 weeks, at visit 10) ] [ Designated as safety issue: No ]
  • Evaluate the pharmacokinetics of AZD8055; Pharmacokinetic analysis of the plasma and urine concentration data for AZD8055 and its metabolites will be performed following both single and multiple dosing with two intermittent dosing schedules. [ Time Frame: 1 cycle (3-4 weeks, at visit 11) ] [ Designated as safety issue: No ]
  • Safety and tolerability of AZD8055; The number of patients with adverse events, including changes in vital signs, general organ function, clinical chemistry, haematology, urinalysis and physical examinations. [ Time Frame: Evaluability period is 5 weeks (visit 5 to visit 14), although safety and tolerability parameters will be measured at all visits. ] [ Designated as safety issue: Yes ]
  • Evaluate the pharmacokinetics of AZD8055; Pharmacokinetic analysis of the plasma and urine concentration data for AZD8055 and its metabolites will be performed following both single and multiple dosing with two intermittent dosing schedules. [ Time Frame: 1 cycle (3-4 weeks, at visits 2, 3, 4, 6-11) ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01194193 on ClinicalTrials.gov Archive Site
  • Preliminary assessment of the anti-tumour activity of AZD8055; Evalution of tumour response using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 and percentage change in tumour size and measurement of serological biomarkers. [ Time Frame: Every 2 cycles (at visits 1, 17, every subsequent 8 weeks, visit 100 ] [ Designated as safety issue: No ]
  • Investigation of possible relationships between plasma AZD8055 concentrations / exposure and changes in safety parameters (including number and types of adverse events). [ Time Frame: 1 cycle (3-4 weeks, at visits 2, 3, 4, 6-11) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of the m-Tor Kinase Inhibitor AZD8055 Using Intermittent Dosing Schedules in Patients With Advanced Solid Malignancies and Lymphomas

To investigate the safety and tolerability of AZD8055 intermittent dosing schedules when given orally to patients with advanced solid malignancies and lymphomas. Two intermittent dosing schedules will be explored with increasing doses until a maximum tolerated dose is determined for each schedule.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Cancer
  • Advanced Solid Tumours
  • Lymphomas
Drug: AZD8055
Oral tablet, single dose on Day 1, followed by a 48 hour - 7 day washout and then either twice daily alternate days dosing from multiple dose day 1 onwards or twice daily dosing for 21 days from multiple dose day 1 onwards followed by 7 days no treatment. Cycles of 28 days.
Experimental: 1
Intervention: Drug: AZD8055
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
63
Not Provided
Not Provided

Inclusion Criteria:

  • Histological or cytological confirmation of an advanced solid malignant tumour or lymphoma which is refactory to standard therapies or for which no standard therapy exists, patients with measurable or non-measurable disease (according to RECIST criteria)
  • WHO performance status 0-2
  • Evidence of post-menopausal status or negative urine/serum pregnancy test for pre-menopausal female patients

Exclusion Criteria:

  • Patients with severe laboratory abnormalities for haematology, liver or renal function. Also treatment with any haemopoietic growth factors are not allowed within two weeks from first dose of study drug.
  • Any investigational agents or study drugs from a previous clinical study within 30 days, any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of the first dose of study treatment
  • Patients with severe cardiac condition of ischemia, impaired ventricular function and arrhythmias, evidence of severe or uncontrolled systemic or current unstable or uncompensated respiratory or cardiac conditions
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01194193
D1600C00002
No
MSD, AstraZeneca
AstraZeneca
Not Provided
Study Director: Ian Smith, MD AstraZeneca R&D
AstraZeneca
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP